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Background: Patient decision aids (P-DAs) are used to inform patients about healthcare choices, but there is
limited knowledge about their longer term effects, beyond the time period of decision-making.
Methods/Design: We developed a computerized P-DA that explains the choice of radioactive iodine (RAI) adjuvant
treatment or no RAI, for patients with low risk papillary thyroid cancer after total thyroidectomy. The original protocol
for a randomized controlled trial, comparing the use of the P-DA (with usual care) to usual care alone, has
been published in Trials http://www.trialsjournal.com/content/11/1/81. We found that P-DA (with usual care)
significantly improved patients’ medical knowledge at the time of decision-making (primary outcome) compared to usual
care alone (control). In this update, we present the protocol for an extended follow-up study (15 to 23 months
post-randomization), including qualitative and quantitative methods. The patient outcomes evaluated using
quantitative questionnaires include: the degree to which patients feel well-informed about their RAI treatment
choice, decision satisfaction, decision regret, cancer-related worry, mood, and trust in the treating physician.
The qualitative component explores the experiences of RAI treatment decision-making, treatment satisfaction,
and trial participation in a representative subgroup of patients. Extended follow-up study results will be described
for the entire study population, and data will be compared between the P-DA and control groups.
Result and Conclusion: This mixed methods extended follow-up study will provide data on long term outcomes, relating
to the use of a computerized P-DA in decision-making about adjuvant RAI treatment in early stage papillary thyroid cancer.
Discussion: Our results are intended to inform future research in this area, particularly relating to long term effects of the
use of P-DAs in making healthcare choices.
Trial registration: Clinicaltrials.gov identifier NCT01083550, registered 24 February 2010 and last updated 5 January 2015
Keywords: Papillary thyroid cancer, Decision aid, Knowledge translation, Patient satisfactionUpdate
Background
Papillary thyroid cancer is rapidly increasing in incidence
throughout the world [1], with some of the greatest in-
creases in incidence observed in relatively low risk dis-
ease that is confined to the thyroid [1–3]. In patients
with low risk papillary thyroid cancer treated with total* Correspondence: sawkaam@yahoo.com
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(RAI) (remnant ablation) is subject to evidence uncer-
tainty, and thus treatment is individualized [4, 5].
Greater emphasis on incorporating patients into the
treatment decision-making process has recently been
recommended by thyroid cancer experts [5].
We previously developed a computerized patient deci-
sion aid (P-DA) that explains the choice of RAI adjuvant
treatment or no RAI, for patients with low risk papillary
thyroid cancer after total thyroidectomy. This is the first
P-DA in the field of thyroid cancer care. The protocol
for the randomized controlled trial, comparing the useticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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been published in Trials [6]. We also previously reported
the results of the primary outcome analysis of this trial,
indicating that P-DA (with usual care) significantly im-
proved patients’ medical knowledge at the time of
decision-making compared to usual care alone [7].
Furthermore, in a secondary analysis, decisional conflict
was significantly reduced in the P-DA group compared
to the control group, at the time of decision-making [7].
However, the rate of RAI use was not significantly differ-
ent between groups [7]. In a pre-planned mixed methods
analysis examining the process of RAI decision-making
from the perspective of patients, treating physicians were
the most frequently cited information source upon
which the decision-making was based [8]. Furthermore,
patients’ perceptions of malignancy threat (current or fu-
ture), relative to the valuation of negative aspects of the
treatment (such as side effects or including uncertainty
of treatment benefit), strongly influenced RAI treatment
choice [8]. In another pre-planned secondary analysis, in
which we explored the relationship between individual
information preference and knowledge acquisition in P-
DA users, we found that individuals with a high moni-
toring information preference accessed more detailed
information from our P-DA program [9]. However,
high monitoring information preference was not sig-
nificantly associated with increased medical knowledge
in P-DA users [9].
In this update, we outline amendments to our proto-
col, including extending follow-up of study participants,
after securing additional research funding. The overall
aim of our follow-up study is to explore the longer term
impact of a thyroid cancer P-DA, from patients’ perspec-
tives. The findings of this secondary study are intended
to generate hypotheses on the long term psychosocial
impact of P-DAs in the context of treatment of low risk
papillary thyroid cancer, using both quantitative and
qualitative research methods.
Methods
This is a single-center, parallel design, randomized con-
trolled trial, in which 74 adults with low risk papillary thy-
roid cancer were randomized in a 1:1 fashion (using
computerized randomization), to a one-time viewing of a
patient-directed computerized P-DA (with usual care), or
no P-DA (with usual care) (Clinicaltrials.gov identifier
NCT01083550 [6, 7]). Prior to randomization, the study
participants, research study personnel, investigators, and
treating physicians were blinded to the allocation [6, 7].
However, following randomization (and immediate admin-
istration of the P-DA intervention for the P-DA group),
the participants, research study personnel, and treating
physicians were not blinded. The extended follow-up study
is un-blinded. The P-DA includes an explanation of risks,benefits, evidence uncertainties, and follow-up implications
of the choice of adjuvant RAI treatment or no adjuvant
RAI treatment. In the original trial protocol, the patients
were followed up on until the treatment decision was final-
ized (between six and 12 months) [6, 7]. An amendment
occurred in the protocol, after publication of the original
design [6], specifically relating to measurement of a sec-
ondary outcome of satisfaction in patient participants and
physicians, utilizing a proposed modification of the Client
Satisfaction Questionnaire-8 (CSQ-8) [10]. We were denied
permission from the developer of the CSQ-8 questionnaire
to modify the form for our study, so this outcome was not
pursued. The amended protocol was approved by the
University Health Network Research Ethics Board, Toronto,
Canada. (UHN REB study identifier: 09-0986-BE).
Following initiation of the original trial, we pursued
and have been granted additional funding to examine
longer term outcomes in our study population. The ex-
tended follow-up study has been approved by the Univer-
sity Health Network Research Ethics Board (UHN REB
study identifier: 09-0986-BE) and participants provide
consent for participation in the study. In this extended
follow-up protocol, enrolled randomized participants are
contacted by telephone between 15 and 23 months post-
randomization, to inquire about interest in participating in
a one-time telephone interview, in which demographic and
thyroid cancer medical and treatment history are updated
and several quantitative questionnaires are administered
by phone (Fig. 1). Questionnaires utilized in the telephone
interview will include: the degree to which patients feel
well-informed about their RAI treatment choice [11], deci-
sion satisfaction [11], decision regret [12, 13], cancer-
related worry (Assessment of Survivor Concerns) [14],
mood [15, 16], and trust in the treating physician [17].
Permission has been sought and granted from devel-
opers for the use of all of these questionnaires.
Participants who agree to the phone interview are also
asked for consent for relevant medical record review and
contact for an in-depth in-person qualitative study (all
approved by the University Health Network Research
Ethics Board). The medical record review includes col-
lection of information relevant to thyroid cancer disease
status, treatment, and follow-up, within the University
Health Network electronic medical record or within
relevant paper-based records obtained from treating
physicians (or the patients themselves), according to the
individual patient’s consent, and where their thyroid can-
cer care is conducted. Patients providing consent for con-
tact of treating physicians are asked to list which physicians
may be contacted (including primary care of thyroid cancer
specialty physicians or surgeons). Physicians are only
contacted for paper-based medical records, and only if
consent has been provided from the patient for this pur-
pose. All medical record review data are summarized on
Fig. 1 Overview of the study, including update of related publications. For results of questionnaires at the time of medical decision-making
and mixed methods analysis results, see Sawka et al. [7, 8]. PTC, papillary thyroid cancer; RAI, radioactive iodine
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and verified by the primary investigator.
In the qualitative component of the extended follow-up
study, a representative subgroup of about 15 to 30 con-
senting participants are invited for an in-person in-depth
interview. The criteria used for purposive sampling of par-
ticipants for the qualitative study include: sex, exposure to
the P-DA, and RAI treatment status (that is, having re-
ceived RAI or not). We strive to achieve equal representa-
tion of P-DA users and those not exposed to the P-DA in
the qualitative study, and within each of these trial groups,
ensuring some representation of those who took RAI as
well as those who did not, within each of these study arms.
The rationale for ensuring some representation of those
taking RAI as well as those not taking RAI within therespective P-DA and non-PDA subgroups, is to enable ex-
ploration of the potential effects of P-DA exposure accord-
ing to the RAI treatment status. In the qualitative study,
we strive for a similar sex distribution in both the P-DA
and non-P-DA groups, to that observed in the original trial
population, largely reflecting the female predisposition to
thyroid cancer, but still ensuring some representation from
males in both the P-DA and non-PDA groups.
The individual interview is performed by a researcher
with experience in qualitative methods, is audio-recorded,
and transcribed per verbatim. Interview questions are de-
signed to elicit patients’ perceptions in the following broad
areas: the process of RAI treatment decision-making, thy-
roid cancer treatment satisfaction (and related psychosocial
factors), and trial participation. Specifically, participants are
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sions were made, including information sources, and extent
of personal involvement in decision-making. Partici-
pants are also asked to elaborate on their overall sat-
isfaction with their thyroid cancer care experience,
including positive and negative aspects of their ex-
perience, any regrets related to the RAI treatment
decision, and ongoing worry related to thyroid cancer
or its treatment. In addition, participants are asked
whether participating in this trial (including exposure to
the P-DA or no exposure to the P-DA or any study related
follow-up) may have impacted them, and if so, how (for
example, influence on RAI-treatment decision-making,
thyroid cancer treatment experience, outlook on life, on-
going thyroid cancer-related worry, relationships with the
treating physicians or others, or any other way). Partici-
pants are also provided the opportunity to provide any
open-ended comments about their experiences or the
study.
The rationale for selection of the time period of 15 to 23
months post-randomization for this follow-up study, is that
it would allow sufficient time for the initial outcome of par-
ticipants to have been ascertained and communicated to
patients from their primary physicians, as well as for reso-
lution of acute RAI treatment side effects (if taken). Fur-
thermore, such a time point is considered close enough to
the experience of RAI decision-making that meaningful
feedback about the experience could be obtained from par-
ticipants. This timeline was also chosen given its feasibility,
as only one year of funding was approved for the extended
follow-up study. All outcomes evaluated in the extended
follow-up study are considered secondary and hypothesis-
generating.
Demographic and clinical characteristics are summarized
for the entire group, as well as for the decision aid and
control groups, respectively. Quantitative questionnaires
are scored according to instructions from their developers.
The quantitative analysis will describe the results of the
quantitative questionnaires in the entire study population
and both groups, for all individuals consenting to the ex-
tended follow-up study. The results of quantitative ques-
tionnaires are compared between the P-DA and control
groups, using unpaired Student’s t tests. Missing data for
any questionnaire subscales is imputed using the mean of
the remaining quantitative responses within that subscale
(for questionnaires in which subscales are established). An
alpha level of 0.05 is established as the cut-off for statistical
significance for all comparative analyses, by convention. As
the secondary analyses in the extended follow-up study are
considered hypothesis-generating, we did not statistically
adjust for multiple comparisons, therefore the results will
need to be confirmed with future research.
In the qualitative study, purposive participant sampling is
continued until saturation of themes is achieved. Contentanalysis of the qualitative data is completed manually, and
the major themes are identified using a grounded theory
approach [18–20]. The extracted themes and related quotes
are reviewed with a content expert (AMS) for further clari-
fication, as needed.
Conclusions
There are limited data on the long term impact of P-DAs,
as most of the existing trial outcomes have been evaluated
at relatively short term time points (that is, one year or
less after the healthcare decision) [21]. Thus, this extended
follow-up study will provide important insights on longer
term outcomes of P-DAs, including important question-
naire outcomes not traditionally studied in the area of P-
DAs such as cancer-related worry, physician trust, as well
as qualitative data from patients’ perspectives. This study
will also inform the importance of future research in long
term outcome research for decision support interventions.
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